Palvella Therapeutics, Inc. $PVLA Shares Sold by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP reduced its position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 24.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 95,259 shares of the company’s stock after selling 30,000 shares during the period. Palvella Therapeutics makes up about 1.8% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 19th biggest holding. Blue Owl Capital Holdings LP’s holdings in Palvella Therapeutics were worth $5,972,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of PVLA. Federated Hermes Inc. acquired a new position in Palvella Therapeutics during the 3rd quarter worth about $21,255,000. Aspiriant LLC acquired a new position in Palvella Therapeutics in the 3rd quarter valued at about $367,000. Aberdeen Group plc purchased a new stake in Palvella Therapeutics during the third quarter worth about $3,212,000. Frazier Life Sciences Management L.P. increased its stake in Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after purchasing an additional 32,388 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Palvella Therapeutics during the second quarter worth about $399,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on PVLA. HC Wainwright raised their price objective on shares of Palvella Therapeutics from $200.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Truist Financial set a $210.00 target price on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Craig Hallum assumed coverage on shares of Palvella Therapeutics in a research report on Thursday, December 4th. They issued a “buy” rating and a $175.00 price target for the company. Oppenheimer restated an “outperform” rating and issued a $200.00 price target on shares of Palvella Therapeutics in a research note on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Palvella Therapeutics in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $184.87.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $134.39 on Friday. The business has a 50-day simple moving average of $97.42 and a 200-day simple moving average of $83.03. Palvella Therapeutics, Inc. has a one year low of $18.23 and a one year high of $151.18. The company has a market cap of $1.59 billion, a PE ratio of -51.10 and a beta of -0.30.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Elaine J. Heron purchased 2,400 shares of the stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $125.00 per share, with a total value of $300,000.00. Following the acquisition, the director directly owned 47,812 shares in the company, valued at $5,976,500. This represents a 5.28% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 20.50% of the stock is owned by insiders.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.